MedPath

A clinical trial to test the safety and effectiveness of combination therapy of 2 Ayurvedic products from Jammi Pharmaceuticals for treating women with PCOS

Phase 3
Completed
Conditions
Health Condition 1: E282- Polycystic ovarian syndrome
Registration Number
CTRI/2021/07/034951
Lead Sponsor
Jammi Pharmaceuticals Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Young women of age between 18 to 40 yrs. diagnosed withPCOS

2.Sub-fertilefemales

3.Polycystic ovaries with exclusion of otheraetiologies

4.Women with normal uterinecavity

5.Subjects with history of Impaired Glucose Tolerance or Insulin Resistance with PCOS

6.Normal physical activity confirmed with physical and clinical examination, and routine laboratory tests, including AST, ALT, haematology routine urinalysis and measurement of oral temperature and vitalsigns.

Exclusion Criteria

1.Pregnant or lactatingwomen.

2.Subjects with presence of infertility factors other thananovulation

3.Subjectswithpelvicorganicpathologies,presenceofotherpathologiessuchasnon- classical congenital adrenal hyperplasia, Cushing’s syndrome and androgen secretingtumours

4.Subjects with thyroid dysfunction, hyperprolactenemia, androgen secreting neoplasia.

5.Women requiring, glucocorticoids, antiandrogens, ovulation induction agents, antidiabetic and anti-obesity drugs, or other hormonaldrugs.

6.Subjects with any neoplastic, metabolic, and cardiovascular disorder or other concurrent medical illness (i.e., type 1 or type 2 diabetes, renal disease, and mal- absorptivedisorders,acuteandchronicinflammations)confirmedbasedonmedical history, physical examination, and routine laboratory tests, including measurement of oral temperature, white blood cell count andurinalysis.

7.Subjects with known history of hypersensitivity to the studydrugs.

8.Alcoholic consumers andsmokers

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
•To evaluate the efficacy of Suventris Syrup and CystEvit Tablet combination therapy when compared to standard of care in eviction of ovarian cysts in subjects diagnosed with Poly-Cystic OvarianSyndromeTimepoint: 120 days
Secondary Outcome Measures
NameTimeMethod
•To evaluate the number of subjects showing normal ovulation after Suventris Syrup and CystEvit Tablets combination therapy when compared to stand ofcare.Timepoint: 120 days
© Copyright 2025. All Rights Reserved by MedPath